Biogen Idec Inc (BIIB.O)


BIIB.O on Nasdaq

203.80USD
19 Jun 2013
Price Change (% chg)

$-7.00 (-3.32%)
Prev Close
$210.80
Open
$210.47
Day's High
$211.26
Day's Low
$203.59
Volume
1,213,582
Avg. Vol
1,494,928
52-wk High
$242.64
52-wk Low
$134.00

BIIB.O

Chart for BIIB.O

About

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company... (more)

Overall

Beta: 0.88
Market Cap (Mil.): $50,038.61
Shares Outstanding (Mil.): 237.37
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 33.48 40.13 30.65
EPS (TTM): 6.30 -- --
ROI: 18.16 2.36 18.83
ROE: 22.05 3.58 19.74
Search Stocks

Divisive Elan boss Martin faces ownership showdown

DUBLIN/NEW YORK - When Kelly Martin, a former Merrill Lynch banker with no drug industry experience, took over as CEO of Ireland's Elan in 2003, analysts assumed his mandate was to clean up the troubled company and sell it.

13 Jun 2013

Biogen delays MS drug's EU launch to secure market exclusivity

May 30 - Biogen Idec Inc expects a delay in the European launch of its multiple sclerosis drug Tecfidera as the drugmaker works to secure exclusive data that could potentially protect its treatment from generic competition for a longer period.

30 May 2013

Biogen profit beats estimates, raises 2013 forecast

- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.

25 Apr 2013

UPDATE 3-Biogen profit beats estimates, raises 2013 forecast

April 25 - Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.

25 Apr 2013

BRIEF-Biogen sees Tecfidera becoming leading oral drug MS drug

April 25 - Biogen Idec Inc : * Says believes tecfidera will become leading oral drug in ms market

25 Apr 2013

Biogen profit beats estimates, raises 2013 forecast

- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday, helped by low taxes and sales growth of its injectable multiple sclerosis treatments, and the U.S. biotechnology company raised its full-year forecast.

25 Apr 2013

Biogen profit beats estimates, raises 2013 forecast

- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday, helped by low taxes and sales growth of its injectable multiple sclerosis treatments, and the U.S. biotechnology company raised its full-year forecast.

25 Apr 2013

Biogen profit beats estimates, helped by lower taxes

- Biogen Idec Inc reported stronger-than-expected quarterly earnings, helped by unusually low taxes and sales growth of its treatments for multiple sclerosis.

25 Apr 2013

Biogen profit beats estimates, helped by lower taxes

April 25 - Biogen Idec Inc reported stronger-than-expected quarterly earnings, helped by unusually low taxes and sales growth of its treatments for multiple sclerosis.

25 Apr 2013

Elan completes sale of Tysabri stake to Biogen

DUBLIN - Irish drugmaker Elan closed the sale of its 50 percent stake in multiple sclerosis (MS) drug Tysabri on Tuesday, clearing the way for it to return cash to investors, spend on acquisitions and stave off an approach for the company.

02 Apr 2013

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF67.15 0.00
Teva Pharmaceutical Industries Limited (TEVA.TA) 14,220.00₪ +100.00
Sanofi SA (SASY.PA) €80.79 -0.76
Pfizer Inc. (PFE.N) $29.10 -0.30
Genmab A/S (GEN.CO) kr.184.10 -4.70
GlaxoSmithKline plc (GSK.L) 1,665.00p -11.00
Johnson & Johnson (JNJ.N) $84.86 -1.50
Abbott Laboratories (ABT.N) $36.21 -1.30
Amgen, Inc. (AMGN.OQ) $99.18 -2.32
UCB SA (UCB.BR) €39.47 -0.14

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: Datamonitor
$175.00
Provider: Stock Traders Daily
$495.00
Provider: Market Edge
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks